Oncology Medical News about breast cancer risk;dietary intake of isoflavones;estrogen and progesterone receptor status

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status
Breast Cancer Research and Treatment, 03/17/09

Zhang M et al. - In a trial to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor (ER) and progesterone receptor (PR) status, the finding that isoflavones protect against all tumor subtypes of breast cancer have biological plausibility, being supported by evidence from experimental studies.

Methods

Incident cases were 756 female pts with histologically confirmed breast cancer.
1009 age-matched controls were healthy women randomly recruited from outpatient breast clinics.
Isoflavone intake was assessed by face-to-face interview using a validated and reliable food-frequency questionnaire and tumor ER and PR status were obtained from pathologic reports.

Results

Compared with women in the lowest intake quartiles, those in the highest quartile of total isoflavone intake had a reduced risk of all receptor status subtypes of breast cancer with a dose-response relationship.
Adjusted ORs were 0.39 for ER+, 0.32 for ER-, 0.43 for PR+, and 0.30 for PR-.
These inverse associations existed in both pre- and post-menopausal women after stratification.
Stronger evidence of a protective effect of high isoflavone intake was observed for breast cancer tumors with concordant rather than discordant receptor status; ie, those with ER+/PR+ and ER-/PR-.

<< Previous
The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+...

Next >>
Genetic variation in genes of the fatty acid synthesis pathway...

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09 Relevance Score: 86%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09 Relevance Score: 85%

Breast-feeding the last born child and risk of ovarian cancer
Cancer Causes and Control, 11/16/09 Relevance Score: 84%

New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk
Archives of Internal Medicine, 10/13/09 Relevance Score: 84%

Novel breast tissue feature strongly associated with risk of breast cancer
Journal of Clinical Oncology, 10/08/09 Relevance Score: 84%